文献速递骨质疏松与代谢性骨病

肾移植后骨密度变化:法国队列的2年评估

Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
PubMed 文献 · Osteoporos Int · 2018-03-02

该纵向研究纳入259例2005至2011年在里尔地区大学医院接受肾移植的患者,首次骨评估于移植后平均9个月进行,2年后复查骨密度。所有患者腰椎、股骨颈和全髋骨密度较基线显著增加,双膦酸盐治疗者和早期停用糖皮质激素者骨密度增益更高。

要点

  • 肾移植受者移植后第一年骨脆性风险增加。
  • 双膦酸盐和早期停用糖皮质激素可改善骨密度。
  • 所有患者第二次评估时腰椎、股骨颈和全髋骨密度较基线显著增加。

核心结论

  • 肾移植受者在移植后第一年骨脆性风险增加,双膦酸盐和早期停用糖皮质激素可改善骨密度。

研究设计与样本

  • 纵向研究,纳入2005至2011年在里尔地区大学医院接受肾移植并随访、且完成首次骨评估(含骨密度测定、脊柱X线和生物学评估)和至少另一次骨密度评估的患者,共259例(366例中满足纳入标准),其中女性96例。

主要发现

  • 移植时平均年龄49.7±12.1岁,平均透析时长3.2±3.3年。
  • 75例(29.0%)在移植后7天停用糖皮质激素且随访期间未再使用。
  • 基线X线评估发现28例(10.8%)存在椎体骨折。
  • 首次评估时按WHO分类,106例(40.9%)有骨质疏松,111例(42.8%)有骨量减少。
  • 所有患者第二次评估(2.2±0.79年)时腰椎、股骨颈和全髋骨密度较基线增益分别为3.9±6.6%、2.6%±7.6%和3.0±7.2%(p<0.0001)。

关键数值与推荐

  • 双膦酸盐治疗与未治疗患者骨密度增益差异显著:腰椎+5.0±0.8%(p<0.0001)、股骨颈+2.5±1.0%(p=0.01)、全髋+2.7±0.9%(p<0.01)。
  • 早期停用糖皮质激素者较维持糖皮质激素治疗者腰椎骨密度增益更高(+2.1±0.9%;p=0.02),全髋骨密度增益更高(+2.0±1.0%;p=0.04)。
  • 逐步回归分析(未用双膦酸盐患者)显示股骨颈骨密度变化与糖皮质激素治疗时长、基线骨碱性磷酸酶水平及无椎体骨折相关。
  • 骨密度变化与透析时长或肾功能无相关性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In renal transplant patients, bone loss may be related to the drugs patients are taking but also to their past history of chronic kidney disease. The purpose of this study was to assess changes in BMD 2 years after an initial assessment (performed 9 months post transplantation) and the factors associated with these changes. METHODS: This longitudinal study included patients who had undergone a renal transplantation between 2005 and 2011, and who were followed up at the Lille Regional University Hospital. Patients were included if they had a first bone evaluation (including bone densitometry, spine X-rays and biological assessment) and at least another BMD assessment. The first assessment was performed on average 9 months post transplantation. A second assessment was performed at 2 years. RESULTS: Two hundred fifty-nine out of 366 patients satisfied the inclusion criteria. The population included 96 women. Mean age at transplantation was 49.7 ± 12.1 years. Mean duration of dialysis was 3.2 ± 3.3 years. For 75 patients (29.0%), corticosteroid treatment was discontinued 7 days after transplantation without subsequent resumption during follow-up. Vertebral fractures assessed by X-rays at baseline were found in 28 patients (10.8%). According to the WHO classification, 106 patients (40.9%) patients had osteoporosis and 111 patients (42.8%) had osteopenia at the first assessment. Oral bisphosphonates were prescribed for 95 patients. The decision to prescribe bisphosphonates was taken jointly by rheumatologists and nephrologists based on BMD assessment, past history of fracture and corticosteroid management. In all patients, BMD gains at the second evaluation (2.2 ± 0.79 years) compared with baseline were significant (3.9 ± 6.6, 2.6% ± 7.6, 3.0 ± 7.2% at the lumbar spine, femoral neck and total hip respectively; p < 0.0001). The difference in gain between bisphosphonate-treated and untreated patients was significant (+ 5.0 ± 0.8% (p < 0.0001), + 2.5 ± 1.0% (p = 0.01) and + 2.7 ± 0.9% (p < 0.01) at the lumbar spine, femoral neck and total hip respectively. The patients who benefited early corticosteroid discontinuation had higher gains in BMD at the lumbar spine (+ 2.1 ± 0.9%; p = 0.02) and total hip (+ 2.0 ± 1.0%; p = 0.04) compared to those for whom corticosteroid therapy was maintained. Stepwise regression analysis (patients without bisphosphonates) showed associations between change in BMD (femoral neck) and duration of corticosteroid therapy, bone alkaline phosphatase level at baseline, and absence of vertebral fracture. No correlation was found between change in BMD and duration of dialysis or renal function. CONCLUSION: Kidney transplant recipients have an increased risk of bone fragility in the year following transplantation. Bisphosphonates and early corticosteroid discontinuation can improve BMD.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Segaud N, Legroux I, Hazzan M, et al. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort. Osteoporos Int. 2018. PMID: 29500526. doi:10.1007/s00198-018-4383-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。